Literature DB >> 15196855

Stromal invasion of the cervix can be excluded from the criteria for using adjuvant radiotherapy following radical surgery for patients with cervical cancer.

Muneaki Shimada1, Junzo Kigawa, Masakuni Takahashi, Yukihisa Minagawa, Makoto Okada, Yasunobu Kanamori, Hiroaki Itamochi, Tetsuro Oishi, Takahiro Iba, Naoki Terakawa.   

Abstract

BACKGROUND: Regarding complications of radiotherapy, the indications for adjuvant radiotherapy should be restricted. We conducted the present study to determine whether deep stromal invasion of the cervix could be excluded from the criteria used to identify patients for this treatment surgery.
METHODS: This study included 115 patients with FIGO stage Ib to IIb cervical cancer who underwent radical hysterectomy and pelvic lymph node dissection. Patients had the following tumors: 61 nonkeratinizing squamous cell carcinoma, 21 keratinizing squamous cell carcinoma, 26 adenocarcinoma, and 7 adenosquamous cell carcinoma. Our study criteria for using adjuvant radiotherapy included positive lymph node involvement, a compromised surgical margin, or parametrial extension. Deep stromal invasion of the cervix was excluded from the criteria in this study.
RESULTS: Seventy-two of the 115 patients (62.6%) underwent radical surgery only and all were alive. The remaining 43 patients received a complete course of external irradiation following radical surgery. The estimated 5-year survival rate is 100% for patients with stage Ib, 93.3% for stage IIa, and 52.7% for stage IIb. Fifty-five patients (47.8%) had deep stromal invasion. The prognosis for patients with deep stromal invasion was significantly worse than that for patients without deep stromal invasion (5-year survival rate, 69.8% vs. 98.0%). However, 21 patients (18.3%) with deep stromal invasion, but without positive lymph node involvement, compromised surgical margin, or parametrial extension, were alive without recurrence. Multivariate analysis showed that lymph node involvement and parametrial extension were independent prognostic factors, but that deep stromal invasion was not.
CONCLUSION: Deep stromal invasion of the cervix can be excluded from the list of criteria for selecting patients with cervical cancer who would benefit from adjuvant radiotherapy following radical surgery.

Entities:  

Mesh:

Year:  2004        PMID: 15196855     DOI: 10.1016/j.ygyno.2004.03.011

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Outcome of stage IB2-IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy.

Authors:  Kazunori Uegaki; Muneaki Shimada; Seiya Sato; Imari Deura; Jun Naniwa; Shinya Sato; Tetsuro Oishi; Hiroaki Itamochi; Tasuku Harada; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2013-04-17       Impact factor: 3.402

2.  Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.

Authors:  Muneaki Shimada; Shoji Nagao; Keiichi Fujiwara; Nobuhiro Takeshima; Ken Takizawa; Tadahiro Shoji; Toru Sugiyama; Satoshi Yamaguchi; Ryuichiro Nishimura; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2016-07-05       Impact factor: 3.402

3.  A low preoperative albumin-to-globulin ratio is a negative prognostic factor in patients with surgically treated cervical cancer.

Authors:  Akira Kawata; Ayumi Taguchi; Satoshi Baba; Yuichiro Miyamoto; Michihiro Tanikawa; Kenbun Sone; Tetsushi Tsuruga; Mayuyo Mori; Katsutoshi Oda; Kei Kawana; Yutaka Osuga; Tomoyuki Fujii
Journal:  Int J Clin Oncol       Date:  2021-01-21       Impact factor: 3.402

4.  Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group.

Authors:  Shogo Shigeta; Muneaki Shimada; Keita Tsuji; Tomoyuki Nagai; Yasuhito Tanase; Koji Matsuo; Shoji Kamiura; Takashi Iwata; Harushige Yokota; Mikio Mikami
Journal:  Int J Clin Oncol       Date:  2022-06-14       Impact factor: 3.850

5.  Clinical experience of pelvic radiotherapy or chemoradiotherapy for postoperative uterine cervical cancer using intensity-modulated radiation therapy.

Authors:  Takaya Yamamoto; Rei Umezawa; Hideki Tokunaga; Masaki Kubozono; Maiko Kozumi; Noriyoshi Takahashi; Haruo Matsushita; Noriyuki Kadoya; Kengo Ito; Kiyokazu Sato; Keita Tsuji; Muneaki Shimada; Keiichi Jingu
Journal:  J Radiat Res       Date:  2020-05-22       Impact factor: 2.724

6.  Chemotherapy versus radiotherapy for FIGO stages IB1 and IIA1 cervical carcinoma patients with postoperative isolated deep stromal invasion: a retrospective study.

Authors:  Lei Li; XiaoYan Song; RuoNan Liu; Nan Li; Ye Zhang; Yan Cheng; HongTu Chao; LiYing Wang
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

7.  The clinical and prognostic implication of deep stromal invasion in cervical cancer patients undergoing radical hysterectomy.

Authors:  Jun Zhu; Lijie Cao; Hao Wen; Rui Bi; Xiaohua Wu; Guihao Ke
Journal:  J Cancer       Date:  2020-10-23       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.